NCT04344717View on ClinicalTrials.gov

Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition

PHASE4RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

December 20, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Short Bowel SyndromeAnticoagulation
Interventions
DRUG

Apixaban single dose

A single dose of apixaban 2.5 mg and 5 mg (wash out period of at least 7 days) will be administered and PK characteristics will be measured

DRUG

Apixaban steady-state

Steady-state apixaban PK characteristics will be measured in patients already treated with apixaban

Trial Locations (1)

3000

RECRUITING

University Hospitals Leuven, Leuven

All Listed Sponsors
lead

Universitaire Ziekenhuizen KU Leuven

OTHER